pharmaceutical preparations

Summary

Summary: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.

Top Publications

  1. pmc DrugBank 3.0: a comprehensive resource for 'omics' research on drugs
    Craig Knox
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 39:D1035-41. 2011
  2. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
  3. pmc Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
  4. pmc PubChem: a public information system for analyzing bioactivities of small molecules
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 37:W623-33. 2009
  5. doi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
  6. pmc DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
  7. pmc A side effect resource to capture phenotypic effects of drugs
    Michael Kuhn
    Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
    Mol Syst Biol 6:343. 2010
  8. pmc Benchmarking sets for molecular docking
    Niu Huang
    Department of Pharmaceutical Chemistry, University of California San Francisco, QB3 Building, 1700 4th Street, Box 2550, San Francisco, California 94143 2550, USA
    J Med Chem 49:6789-801. 2006
  9. pmc STITCH 2: an interaction network database for small molecules and proteins
    Michael Kuhn
    Biotechnology Center, TU Dresden, 01062 Dresden, Germany
    Nucleic Acids Res 38:D552-6. 2010
  10. pmc Exploiting drug-disease relationships for computational drug repositioning
    Joel T Dudley
    Stanford University, Stanford, CA, USA
    Brief Bioinform 12:303-11. 2011

Research Grants

  1. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
  2. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
  3. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 2001
  4. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 1993
  5. Bi(III)-Initiated Chemistry: Mechanistic Investigations of Catalytic Activity
    Robert Hinkle; Fiscal Year: 2007
  6. Label Free Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2007
  7. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2003
  8. Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2005
  9. CHROMATOGRAPHIC AUTOMATION OF IMMUNOASSAYS
    DAVID HAGE; Fiscal Year: 2000
  10. ACYL GLUCURONIDES: COVALENT BINDING & PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 1993

Detail Information

Publications290 found, 100 shown here

  1. pmc DrugBank 3.0: a comprehensive resource for 'omics' research on drugs
    Craig Knox
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 39:D1035-41. 2011
    ..0 represents the result of 2 years of manual annotation work aimed at making the database much more useful for a wide range of 'omics' (i.e. pharmacogenomic, pharmacoproteomic, pharmacometabolomic and even pharmacoeconomic) applications...
  2. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
    ..Recent work on linear free energy relationships and Log P approaches are critically reviewed. Useful predictions are possible in closely related analog series when coupled with experimental thermodynamic solubility measurements...
  3. pmc Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
    ..The chemical similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs...
  4. pmc PubChem: a public information system for analyzing bioactivities of small molecules
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 37:W623-33. 2009
    ..Most of the tools described in this work can be directly accessed at http://pubchem.ncbi.nlm.nih.gov/assay/. URLs for accessing other tools described in this work are specified individually...
  5. doi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
    ..Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs...
  6. pmc DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
    ..DrugBank has also significantly improved the power and simplicity of its structure query and text query searches. DrugBank is available at http://www.drugbank.ca...
  7. pmc A side effect resource to capture phenotypic effects of drugs
    Michael Kuhn
    Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
    Mol Syst Biol 6:343. 2010
    ..We illustrate the potential of SIDER with a number of analyses. The resource is freely available for academic research at http://sideeffects.embl.de...
  8. pmc Benchmarking sets for molecular docking
    Niu Huang
    Department of Pharmaceutical Chemistry, University of California San Francisco, QB3 Building, 1700 4th Street, Box 2550, San Francisco, California 94143 2550, USA
    J Med Chem 49:6789-801. 2006
    ..DUD is freely available online as a benchmarking set for docking at http://blaster.docking.org/dud/...
  9. pmc STITCH 2: an interaction network database for small molecules and proteins
    Michael Kuhn
    Biotechnology Center, TU Dresden, 01062 Dresden, Germany
    Nucleic Acids Res 38:D552-6. 2010
    ..STITCH 2.0 connects proteins from 630 organisms to over 74,000 different chemicals, including 2200 drugs. STITCH can be accessed at http://stitch.embl.de/...
  10. pmc Exploiting drug-disease relationships for computational drug repositioning
    Joel T Dudley
    Stanford University, Stanford, CA, USA
    Brief Bioinform 12:303-11. 2011
    ..Newer algorithms for computational drug repositioning will likely span these two axes, will take advantage of newer types of molecular measurements, and will certainly play a role in reducing the global burden of disease...
  11. pmc An overview of the PubChem BioAssay resource
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 38:D255-66. 2010
    ..In this work, we describe the PubChem BioAssay database, including data model, bioassay deposition and utilities that PubChem provides for searching, downloading and analyzing the biological activity information contained therein...
  12. pmc Update of TTD: Therapeutic Target Database
    Feng Zhu
    Department of Pharmacy and Computation and Systems Biology, Center for Computational Science and Engineering, Singapore MIT Alliance, National University of Singapore, Singapore
    Nucleic Acids Res 38:D787-91. 2010
    ..This database can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD.asp...
  13. pmc Virtual screening of chemical libraries
    Brian K Shoichet
    Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, California 94143 2240, USA
    Nature 432:862-5. 2004
    ....
  14. ncbi ADMET in silico modelling: towards prediction paradise?
    Han van de Waterbeemd
    Pfizer Global Research and Development, PDM, Sandwich, Kent CT13 9NJ, UK
    Nat Rev Drug Discov 2:192-204. 2003
    ..Here, we describe how in silico approaches will further increase our ability to predict and model the most relevant pharmacokinetic, metabolic and toxicity endpoints, thereby accelerating the drug discovery process...
  15. pmc SuperTarget and Matador: resources for exploring drug-target relationships
    Stefan Günther
    Structural Bioinformatics Group, Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 36:D919-22. 2008
    ..SuperTarget and Matador are available at http://insilico.charite.de/supertarget and http://matador.embl.de...
  16. pmc Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
    Yoshihiro Yamanishi
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, Institut Curie, F 75248, INSERM U900, F 75248, Paris, France
    Bioinformatics 26:i246-54. 2010
    ..There is therefore a strong incentive to develop new methods capable of detecting these potential drug-target interactions efficiently...
  17. ncbi Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics
    Christoph Steinbeck
    Cologne University Bioinformatics Center CUBIC, Germany
    Curr Pharm Des 12:2111-20. 2006
    ..This article introduces the CDK's new QSAR capabilities and the recently introduced interface to statistical software...
  18. pmc Supervised prediction of drug-target interactions using bipartite local models
    Kevin Bleakley
    Mines ParisTech, Centre for Computational Biology, Fontainebleau, France
    Bioinformatics 25:2397-403. 2009
    ..This, however, remains extremely challenging due to, amongst other things, the rarity of known drug-target interactions...
  19. pmc KEGG for linking genomes to life and the environment
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto, Japan
    Nucleic Acids Res 36:D480-4. 2008
    ..KEGG DRUG contains all approved drugs in the US and Japan, and KEGG DISEASE is a new database linking disease genes, pathways, drugs and diagnostic markers...
  20. ncbi Relating protein pharmacology by ligand chemistry
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St, San Francisco California 94143 2550, USA
    Nat Biotechnol 25:197-206. 2007
    ..These predictions were subsequently confirmed experimentally. Relating receptors by ligand chemistry organizes biology to reveal unexpected relationships that may be assayed using the ligands themselves...
  21. pmc ChEBI: a database and ontology for chemical entities of biological interest
    Kirill Degtyarenko
    European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
    Nucleic Acids Res 36:D344-50. 2008
    ..ChEBI includes an ontological classification, whereby the relationships between molecular entities or classes of entities and their parents and/or children are specified. ChEBI is available online at http://www.ebi.ac.uk/chebi/..
  22. pmc Identifying the proteins to which small-molecule probes and drugs bind in cells
    Shao En Ong
    Proteomics Platform, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 106:4617-22. 2009
    ..Here, we describe in full detail the application of the method to identify targets of kinase inhibitors and immunophilin binders...
  23. ncbi Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast
    Ainslie B Parsons
    Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario M5G 1L6, Canada
    Cell 126:611-25. 2006
    ..This compendium should serve as a valuable key for interpreting cellular effects of novel compounds with similar activities...
  24. pmc IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data
    Joanna L Sharman
    University BHF Centre for Cardiovascular Science, The Queen s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK
    Nucleic Acids Res 39:D534-8. 2011
    ..The database is freely available at http://www.iuphar-db.org...
  25. ncbi Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance
    Dana W Kolpin
    US Geological Survey, Iowa City, Iowa 52244, USA
    Environ Sci Technol 36:1202-11. 2002
    ....
  26. ncbi Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure
    Andreas Bender
    Lead Finding Platform, Novartis Institutes for BioMedical Research Inc 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA
    ChemMedChem 2:861-73. 2007
    ..In addition, models such as the ones presented here can be used for compound profiling in all development stages...
  27. ncbi Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database
    Ana Szarfman
    Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Drug Saf 25:381-92. 2002
    ..The application of these tools may ultimately improve usage recommendations...
  28. pmc Chemical substructures that enrich for biological activity
    Justin Klekota
    Harvard University Graduate Biophysics Program, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
    Bioinformatics 24:2518-25. 2008
    ..This has led to the claim of 'privileged' substructures which are predisposed to bioactivity. Because bias in screening library construction could explain this phenomenon, the existence of privilege has been controversial...
  29. pmc DrugBank: a comprehensive resource for in silico drug discovery and exploration
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 34:D668-72. 2006
    ..DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/...
  30. ncbi The many roles of computation in drug discovery
    William L Jorgensen
    Department of Chemistry, Yale University, New Haven, CT 06520 8107, USA
    Science 303:1813-8. 2004
    ..Particular emphasis is placed on virtual screening, de novo design, evaluation of drug-likeness, and advanced methods for determining protein-ligand binding...
  31. ncbi Appropriate prescribing in elderly people: how well can it be measured and optimised?
    Anne Spinewine
    Center for Clinical Pharmacy, School of Pharmacy, Universite Catholique de Louvain, Brussels, Belgium
    Lancet 370:173-84. 2007
    ....
  32. ncbi Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
    Christopher J H Porter
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Nat Rev Drug Discov 6:231-48. 2007
    ....
  33. doi Determinants of under-reporting of adverse drug reactions: a systematic review
    Elena Lopez-Gonzalez
    Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain
    Drug Saf 32:19-31. 2009
    ..This result may have important implications in terms of public health, if knowledge and attitudes are viewed as potentially modifiable factors...
  34. ncbi Medication errors and adverse drug events in pediatric inpatients
    R Kaushal
    Children's Hospital, Enders 609, Longwood Avenue, Boston, MA 02115, USA
    JAMA 285:2114-20. 2001
    ..CONCLUSIONS: Medication errors are common in pediatric inpatient settings, and further efforts are needed to reduce them...
  35. pmc A computational approach to finding novel targets for existing drugs
    Yvonne Y Li
    Canada s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    PLoS Comput Biol 7:e1002139. 2011
    ..Novel interactions discovered may lead to the drug being repositioned as a therapeutic treatment for its off-target's associated disease, added insight into the drug's mechanism of action, and added insight into the drug's side effects...
  36. pmc Predicting drug-target interaction networks based on functional groups and biological features
    Zhisong He
    CAS MPG Partner Institute of Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    PLoS ONE 5:e9603. 2010
    ..As a complement, the in silico prediction methods can provide us with very useful information in a timely manner...
  37. ncbi Ecotoxicology of human pharmaceuticals
    Karl Fent
    University of Applied Sciences Basel, Institute of Environmental Technology, Muttenz, Switzerland
    Aquat Toxicol 76:122-59. 2006
    ..This will allow better and comprehensive risk assessments of pharmaceuticals in the future...
  38. pmc Predicting drug side-effect profiles: a chemical fragment-based approach
    Edouard Pauwels
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, France
    BMC Bioinformatics 12:169. 2011
    ....
  39. pmc Pharmaceuticals and personal care products in the environment: what are the big questions?
    Alistair B A Boxall
    Environment Department, University of York, Heslington, York, United Kingdom
    Environ Health Perspect 120:1221-9. 2012
    ..Over the past 10-15 years, a substantial amount of work has been done by the scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals and personal care products (PPCPs) in the environment...
  40. ncbi A robustness-based approach to systems-oriented drug design
    Hiroaki Kitano
    Sony Computer Science Laboratories Inc, 3 14 13 Higashi Gotanda, Shinagawa, Tokyo 141 0022, Japan
    Nat Rev Drug Discov 6:202-10. 2007
    ....
  41. doi Prevalence, incidence and nature of prescribing errors in hospital inpatients: a systematic review
    Penny J Lewis
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Drug Saf 32:379-89. 2009
    ..Future research should address the wide disparity of data-collection methods and definitions that bedevils comparison of error rates or meta-analysis of different studies...
  42. pmc Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments
    Roger Bate
    American Enterprise Institute, Washington, D C, USA
    Malar J 9:157. 2010
    ..Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed...
  43. pmc Systematic evaluation of drug-disease relationships to identify leads for novel drug uses
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 86:507-10. 2009
    ..When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials...
  44. doi 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries
    Paul D Dobson
    School of Chemistry and The Manchester Interdisciplinary Biocentre, The University of Manchester, 131 Princess St, Manchester M1 7DN, UK
    Drug Discov Today 14:31-40. 2009
    ....
  45. ncbi Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry
    Miklos Feher
    SignalGene Inc, 335 Laird Road, Unit 2, Guelph, Ontario, N1G 4P7, Canada
    J Chem Inf Comput Sci 43:218-27. 2003
    ..It is suggested that by mimicking certain distribution properties of natural compounds, combinatorial products might be made that are substantially more diverse and have greater biological relevance...
  46. ncbi Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
    P Ertl
    Cheminformatics, Novartis Pharma AG, WKL 490 4 35, CH 4002 Basel, Switzerland
    J Med Chem 43:3714-7. 2000
    ..This article describes the new methodology and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration...
  47. pmc PROMISCUOUS: a database for network-based drug-repositioning
    Joachim von Eichborn
    Charite Universitatsmedizin Berlin, Institute for Physiology, Structural Bioinformatics Group, Lindenberger Weg 80, 13125 Berlin, Germany
    Nucleic Acids Res 39:D1060-6. 2011
    ..This network-based approach can provide a starting point for drug-repositioning. PROMISCUOUS is publicly available at http://bioinformatics.charite.de/promiscuous...
  48. ncbi Comparison of support vector machine and artificial neural network systems for drug/nondrug classification
    Evgeny Byvatov
    Institut für Organische Chemie und Chemische Biologie, Johann Wolfgang Goethe Universitat, Marie Curie Strasse 11, D 60439 Frankfurt, Germany
    J Chem Inf Comput Sci 43:1882-9. 2003
    ..The theory of SVM and ANN training is briefly reviewed...
  49. pmc From genomics to chemical genomics: new developments in KEGG
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto 611 0011, Japan
    Nucleic Acids Res 34:D354-7. 2006
    ..Additionally, drug information is now stored separately and linked to new KEGG DRUG structure maps...
  50. ncbi Drug-related problems in hospitals: a review of the recent literature
    Anita Krähenbühl-Melcher
    Hospital Pharmacy, Regionalspital Emmental, Burgdorf, Switzerland
    Drug Saf 30:379-407. 2007
    ....
  51. pmc Building the process-drug-side effect network to discover the relationship between biological processes and side effects
    Sejoon Lee
    Bio and Brain Engineering Department, KAIST, Daejeon 305 701, South Korea
    BMC Bioinformatics 12:S2. 2011
    ..To the best of our knowledge, the relationship between biological processes and side effects of drugs has not yet been systematically researched...
  52. doi Adverse drug reactions in childhood: a review of prospective studies and safety alerts
    A Clavenna
    Laboratory for Mother and Child Health, Department of Public Health, Mario Negri Institute for Pharmacological Research, 20156 Milan MI, Italy
    Arch Dis Child 94:724-8. 2009
    ..To assess the incidence of adverse drug reactions (ADRs) in the paediatric population and the safety alerts concerning children and adolescents issued by international drug regulatory agencies since 2001...
  53. pmc Relating drug-protein interaction network with drug side effects
    Sayaka Mizutani
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Gokasho Uji, Kyoto 611 0011, Japan
    Bioinformatics 28:i522-i528. 2012
    ....
  54. doi Impact of solvent conditions on separation and detection of basic drugs by micro liquid chromatography-mass spectrometry under overloading conditions
    Birthe Schubert
    Institute of Legal Medicine, Innsbruck Medical University, Muellerstrasse 44, 6020 Innsbruck, Austria
    J Chromatogr A 1218:3413-22. 2011
    ..Applications of μLC/MS for the qualitative and quantitative analysis of clinical and forensic toxicological samples are presented...
  55. pmc DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome
    Heng Luo
    Bio X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    Nucleic Acids Res 39:W492-8. 2011
    ..This server is freely available at http://cpi.bio-x.cn/drar/...
  56. doi Diagnosing the decline in pharmaceutical R&D efficiency
    Jack W Scannell
    Sanford C Bernstein Limited, 50 Berkeley Street, Mayfair Place, London W1J 8SB, UK
    Nat Rev Drug Discov 11:191-200. 2012
    ..Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency...
  57. ncbi Observational study of potential risk factors of medication administration errors
    Edgar Tissot
    Pharmacy Department, Besancon University Hospital, Boulevard Fleming, 25030 Besancon, France
    Pharm World Sci 25:264-8. 2003
    ..The aims of this observational study were to assess the rate and the potential clinical significance of MAEs and to determine the associated risk factors...
  58. ncbi Global mapping of pharmacological space
    Gaia V Paolini
    The Department of Knowledge Discovery, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK
    Nat Biotechnol 24:805-15. 2006
    ..The relationships between proteins, chemical structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity...
  59. ncbi Aging biology and geriatric clinical pharmacology
    Allan J McLean
    Director, National Ageing Research Institute, P O Box 31, Parkville, VIC Australia
    Pharmacol Rev 56:163-84. 2004
    ..Even so, therapeutic advances generally may convert healthy longevity from an asset of fortunate individuals into a general social benefit...
  60. pmc Extracting medication information from clinical text
    Ozlem Uzuner
    Department of Information Studies, University at Albany, State University of New York, Albany, NY, USA
    J Am Med Inform Assoc 17:514-8. 2010
    ..However, they are limited in recognizing duration and reason fields and would benefit from future research...
  61. pmc The chemical basis of pharmacology
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158 2558, USA
    Biochemistry 49:10267-76. 2010
    ..The bases for these new methods, some of their successes and liabilities, and new opportunities for their use are described...
  62. doi Stability of protein pharmaceuticals: an update
    Mark Cornell Manning
    Legacy BioDesign LLC, Johnstown, Colorado 80534, USA
    Pharm Res 27:544-75. 2010
    ....
  63. doi Sampling for PPCPs in wastewater systems: comparison of different sampling modes and optimization strategies
    Christoph Ort
    The University of Queensland, Advanced Water Management Centre, QLD 4072, Australia
    Environ Sci Technol 44:6289-96. 2010
    ....
  64. ncbi Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital
    Jimmy Jose
    Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576 104, Karnataka, India
    Pharmacol Res 54:226-33. 2006
    ..Our evaluations revealed opportunities for interventions especially for the preventable ADRs to ensure safer drug use...
  65. ncbi Distributions of pharmaceuticals in an urban estuary during both dry- and wet-weather conditions
    Mark J Benotti
    Marine Sciences Research Center, Stony Brook University, Stony Brook, New York 11794 5000, USA
    Environ Sci Technol 41:5795-802. 2007
    ..This observation is consistent with a simple model illustrating the effect of precipitation has on pharmaceutical concentration in the wastewater stream, given the balance between dilution from rain and the bypass of treatment...
  66. ncbi Bioequivalence approaches for highly variable drugs and drug products
    Sam H Haidar
    Office of Generic Drugs, Food and Drug Administration, 7500 Standish Place, Rockville, Maryland, 20855, USA
    Pharm Res 25:237-41. 2008
    ..A partial replicated-treatment design with this new data analysis methodology will thus provide a more efficient design for BE studies with highly variable drugs and drug products...
  67. pmc Finding complex biological relationships in recent PubMed articles using Bio-LDA
    Huijun Wang
    School of Informatics and Computing, Indiana University, Bloomington, Indiana, United States of America
    PLoS ONE 6:e17243. 2011
    ..This combined approach offers new opportunities for knowledge discovery in many areas of biology including target identification, lead hopping and drug repurposing...
  68. ncbi Predicted and measured concentrations for selected pharmaceuticals in UK rivers: implications for risk assessment
    Jonathan P Bound
    Centre for Environmental Policy, Imperial College London, London SW7 2BP, UK
    Water Res 40:2885-92. 2006
    ..Results from one site demonstrated a considerable increase in concentrations of ibuprofen, salbutamol and paracetamol downstream from the treatment works; however, no link was established for a second works...
  69. ncbi Drug-induced inflammatory responses to the lung
    A Ryrfeldt
    Safety Assessment, AstraZeneca, Sodertalje, Sweden
    Toxicol Lett 112:171-6. 2000
    ..In this review a couple of mechanistic aspects, related to drug induced lung injury, will be discussed such as reactive oxygen species (ROS)-generation, mediator release and disturbances in lung phospholipid turnover...
  70. pmc STITCH: interaction networks of chemicals and proteins
    Michael Kuhn
    European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Nucleic Acids Res 36:D684-8. 2008
    ..5 million genes across 373 genomes and their interactions contained in the STRING database. STITCH is available at http://stitch.embl.de/...
  71. doi Determination of multiple pharmaceutical classes in surface and ground waters by liquid chromatography-ion trap-tandem mass spectrometry
    Svetlana Grujic
    Department of Analytical Chemistry, Faculty of Technology and Metallurgy, University of Belgrade, Belgrade, Serbia
    J Chromatogr A 1216:4989-5000. 2009
    ..Confirmation of the positive results was performed by repeated injection of the positive sample extracts using confirmatory method with additional transitions...
  72. pmc Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS
    Gabriel A Silva
    Departments of Bioengineering and Ophthalmology, and Neurosciences Program, University of California San Diego, 9415 Campus Point Drive, La Jolla, CA 92037 0946, USA
    BMC Neurosci 9:S4. 2008
    ..This brief review introduces emerging work in this area and summarizes a number of example applications to CNS cancers, gene therapy, and analgesia...
  73. ncbi Modeling and simulation of preclinical cardiac safety: towards an integrative framework
    Antoine Soubret
    Modeling and Simulation, Novartis Pharma AG, Basel, Switzerland
    Drug Metab Pharmacokinet 24:76-90. 2009
    ....
  74. pmc Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy
    Christian G Daughton
    Environmental Chemistry Branch, Environmental Sciences Division National Exposure Research Laboratory, Office of Research and Development, U S Environmental Protection Agency, Las Vegas, Nevada 89119, USA
    Environ Health Perspect 111:757-74. 2003
    ..A major objective is to generate an active dialog or debate across the many disciplines that must become actively involved to design and implement a successful approach to life-cycle stewardship of PPCPs...
  75. doi Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment
    Lúcia H M L M Santos
    REQUIMTE, Faculty of Pharmacy, University of Porto Rua Anibal Cunha, 164, 4050 047 Porto, Portugal
    J Hazard Mater 175:45-95. 2010
    ..An extensive review of existing data in the form of tables, encompassing many therapeutic classes is presented...
  76. doi Physiochemical drug properties associated with in vivo toxicological outcomes
    Jason D Hughes
    Pfizer Research Technology Center, Cambridge, MA 02139, USA
    Bioorg Med Chem Lett 18:4872-5. 2008
    ..This trend held across a wide range of types of toxicity and across a broad swath of chemical space...
  77. doi Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies
    Chuenjid Kongkaew
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK
    Ann Pharmacother 42:1017-25. 2008
    ..To determine the prevalence of hospital admissions associated with ADRs and examine differences in prevalence rates between population groups and methods of ADR detection...
  78. ncbi Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water
    Mark J Benotti
    Applied Research and Development Center, Southern Nevada Water Authority, P O Box 99954, Las Vegas, Nevada 89193 9954, USA
    Environ Sci Technol 43:597-603. 2009
    ..Atenolol, atrazine, DEET, estrone, meprobamate, and trimethoprim can serve as indicator compounds representing potential contamination from other pharmaceuticals and EDCs and can gauge the efficacy of treatment processes...
  79. pmc Modelling and PBPK simulation in drug discovery
    Hannah M Jones
    Pfizer Global R and D, Department of Pharmacokinetics, Dynamics and Metabolism, IPC 654, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    AAPS J 11:155-66. 2009
    ..Specific reference is made to its utility (1) at the lead development stage for the prioritization of compounds for animal PK studies and (2) at the clinical candidate selection and "first in human" stages for the prediction of human PK...
  80. pmc Sex differences in pharmacokinetics and pharmacodynamics
    Offie P Soldin
    Departments of Medicine, Oncology and Physiology, Center for the Study of Sex Differences, Georgetown University Medical Center, Washington, DC, USA
    Clin Pharmacokinet 48:143-57. 2009
    ..Since this is a rapidly evolving area, it is essential for the practitioner to review drug prescribing information and recent literature in order to fully understand the impact of these differences on clinical therapeutics...
  81. pmc Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts
    Jiao Li
    State Key Laboratory of Intelligent Technology and Systems, Tsinghua National Laboratory for Information Science and Technology, Department of Computer Science and Technology, Tsinghua University, Beijing, China
    PLoS Comput Biol 5:e1000450. 2009
    ....
  82. ncbi Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
    Chi Yuan Wu
    Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143, USA
    Pharm Res 22:11-23. 2005
    ....
  83. ncbi An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
    Neil Parrott
    F Hoffmann La Roche AG, Pharmaceuticals Division, CH 4070 Bl, Switzerland
    J Pharm Sci 94:2327-43. 2005
    ..However verification of the simulations with in vivo data for a few compounds of each compound class is recommended since recent discovery compounds may have properties beyond the scope of the current generic models...
  84. doi Drug effects viewed from a signal transduction network perspective
    Anton F Fliri
    Pfizer Global Research and Development, CT, USA
    J Med Chem 52:8038-46. 2009
    ..These protein network topology models reveal that drugs having similar pharmacology profiles reach similar discrete positions in cellular protein network systems and provide a network view of medicine cause-effect relationships...
  85. ncbi Micellar solubilization of drugs
    Carlota Oliveira Rangel-Yagui
    Department of Biochemical and Pharmaceutical Technology FCF, University of Sao Paulo, Sao Paulo, Brazil
    J Pharm Pharm Sci 8:147-65. 2005
    ..Micellar solubilization is a powerful alternative for dissolving hydrophobic drugs in aqueous environments. In this work, we provide an insight into this subject...
  86. ncbi Physiologically-based pharmacokinetic simulation modelling
    George M Grass
    LION Bioscience, 9880 Campus Point Drive, San Diego, CA 92121, USA
    Adv Drug Deliv Rev 54:433-51. 2002
    ....
  87. ncbi Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales
    Bryan A Liang
    Institute of Health Law Studies, California Western School of Law, San Diego, CA, USA
    Am J Law Med 35:125-84. 2009
    ....
  88. ncbi Graphic rule for drug metabolism systems
    Kuo Chen Chou
    Gordon Life Science Institute, 13784 Torrey Del Mar Drive, San Diego, CA 92130, USA
    Curr Drug Metab 11:369-78. 2010
    ..g., according to their directed graphs, the metabolism of seliciclib and the metabolism of vildagliptin can be categorized as 0-->5 mechanism while that of AG-024322 as 0-->4-->3 mechanism...
  89. doi Chemiluminescence detection in liquid chromatography: applications to clinical, pharmaceutical, environmental and food analysis--a review
    Laura Gámiz-Gracia
    Department of Analytical Chemistry, Faculty of Sciences, Campus Fuentenueva, University of Granada, E 18071 Granada, Spain
    Anal Chim Acta 640:7-28. 2009
    ..The review covers the literature from 2000 until the end of 2008...
  90. ncbi Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
    J Kelder
    Department of Molecular Design and Informatics, NV Organon, Oss, The Netherlands
    Pharm Res 16:1514-9. 1999
    ..To study oral absorption and brain penetration as a function of polar molecular surface area...
  91. pmc Data-driven methods to discover molecular determinants of serious adverse drug events
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics, Stanford University School of Medicine, Stanford, California, USA
    Clin Pharmacol Ther 85:259-68. 2009
    ..We also describe recent examples of how bioinformatics methods coupled with data repositories can advance the science of SADRs...
  92. ncbi A topological substructural approach for the prediction of P-glycoprotein substrates
    Miguel Angel Cabrera
    Department of Drug Design, Centre of Chemical Bioactive, Central University of Las Villas, Santa Clara, Villa Clara, Cuba
    J Pharm Sci 95:589-606. 2006
    ....
  93. pmc SMPDB: The Small Molecule Pathway Database
    Alex Frolkis
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 38:D480-7. 2010
    ..Gene, metabolite and protein concentration data can also be visualized through SMPDB's mapping interface. All of SMPDB's images, image maps, descriptions and tables are downloadable. SMPDB is available at: http://www.smpdb.ca...
  94. doi Mathematical modeling of drug delivery
    J Siepmann
    College of Pharmacy, JE 2491, University of Lille, 3 rue du Professeur Laguesse, 59006 Lille, France
    Int J Pharm 364:328-43. 2008
    ..Ideally, the effects of the design parameters of the dosage form on the resulting drug concentration time profiles at the site of action and the pharmacodynamic effects will become predictable...
  95. ncbi Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
    Nicola J Hewitt
    Scientific Writing Services, Wingertstrasse, Erzhausen, Germany
    Drug Metab Rev 39:159-234. 2007
    ..We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process...
  96. doi Large-scale prediction of drug-target relationships
    Michael Kuhn
    European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    FEBS Lett 582:1283-90. 2008
    ..We finally discuss how phenotypic data could help to expand our understanding of the complex mechanisms of drug action...
  97. ncbi Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
    Shu Feng Zhou
    Division of Chinese Medicine, School of Health Sciences, WHO Collaborating Center for Traditional Medicine, RMIT University, Victoria, Australia
    Curr Drug Metab 9:310-22. 2008
    ....
  98. ncbi Computation of octanol-water partition coefficients by guiding an additive model with knowledge
    Tiejun Cheng
    State Key Laboratory of Bioorganic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai, P R China
    J Chem Inf Model 47:2140-8. 2007
    ..It is also able to utilize the ever-increasing experimentally measured logP data more effectively...
  99. ncbi Timing of new black box warnings and withdrawals for prescription medications
    Karen E Lasser
    Department of Medicine, Cambridge Hospital, Cambridge, MA 02139, USA
    JAMA 287:2215-20. 2002
    ..Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs...
  100. ncbi Structure-based virtual screening: an overview
    Paul D Lyne
    AstraZeneca R and D Boston, Waltham, MA 02451, USA
    Drug Discov Today 7:1047-55. 2002
    ..Here, the current strengths and weaknesses of the technology are discussed, and emphasis is placed on aspects of the work-flow of a virtual screening campaign, from preparation through to post-screening analysis...
  101. ncbi Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
    Kelly M Mahar Doan
    Preclinical Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 303:1029-37. 2002
    ..For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B --> A/A --> B ratio <2.5) Pgp substrate...

Research Grants146 found, 100 shown here

  1. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
    ..problem resulting from the use of Mn as a gasoline additive, and its use in welding rods, pesticides, pharmaceutical preparations, alloy manufacturing, and in dry cell battery production, for instance...
  2. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
    ..problem resulting from the use of Mn as a gasoline additive, and its use in welding rods, pesticides, pharmaceutical preparations, alloy manufacturing, and in dry cell battery production, for instance...
  3. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 2001
    ..The synthesis characterization and physicochemical studies will be carried out at Texas A&M University while the in vitro and in vivo evaluation of the pharmaceutical preparations will be undertaken at Washington University.
  4. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 1993
    ..and physicochemical studies will be carried out at Texas A&M University with non-radioactive isotopes while in vitro and in vivo evaluation of the pharmaceutical preparations will be carried out at Washington University.
  5. Bi(III)-Initiated Chemistry: Mechanistic Investigations of Catalytic Activity
    Robert Hinkle; Fiscal Year: 2007
    ..In fact, bismuth compounds have been widely utilized in pharmaceutical preparations for over 400 years...
  6. Label Free Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2007
    ..However, an anticounterfeiting method to protect pharmaceutical preparations directly at the pill level presents a singularly stringent set of requirements in terms of employing a ..
  7. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2003
    ..The stabilization of DNA in viable long-term pharmaceutical preparations is one critical part toward the advance of gene therapy to the clinic...
  8. Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2005
    ..has prevented any of these techniques from evolving into a widely used and effective system to protect pharmaceutical preparations. Parallel Synthesis Technologies proposes the use of an inexpensive and easy to use encoding technology,..
  9. CHROMATOGRAPHIC AUTOMATION OF IMMUNOASSAYS
    DAVID HAGE; Fiscal Year: 2000
    ..As these assay systems are developed and evaluated, their extension to the determination of other free drugs or hormones, plus the simultaneous measurement of free and bound solute fractions, will also be considered. ..
  10. ACYL GLUCURONIDES: COVALENT BINDING & PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 1993
    ..investigate the relationship between irreversible binding in vivo and immunological toxicity...
  11. ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 2002
    ....
  12. Metabolism of Carcinogens and Drugs by Human P450s
    F Guengerich; Fiscal Year: 2007
    ....
  13. BIOACTIVATION OF HALOGENATED HYDROCARBONS
    F Guengerich; Fiscal Year: 2005
    ..These experiments involving enzymatic oxidation and conjugation reactions are intended to help define important concepts that can be applied to other halogenated hydrocarbons and to other cancer suspect chemicals as well. ..
  14. Polymerase Interactions with Carcinogen-modified DNA
    F Peter Guengerich; Fiscal Year: 2010
    ..The goals of this project involve understanding how the DNA polymerases make such mistakes. ..
  15. Novel Approaches to Blood Brain Barrier Function
    Alex Avdeef; Fiscal Year: 2007
    ....
  16. Annotating functional sites in 3D biological structures
    RUSS BIAGIO ALTMAN; Fiscal Year: 2010
    ..In particular, we will focus our new capabilities on three difficult function annotation challenges: ATP binding sites, phosphorylation sites, and metabolizing enzyme active sites. ..
  17. Physics-based Simulation of Biological Structures(RMI)
    Russ Altman; Fiscal Year: 2007
    ..It will thus provide a critical piece of a national biomedical computing infrastructure. ..
  18. CHROMATOGRAPHIC AUTOMATION OF IMMUNOASSAYS
    DAVID HAGE; Fiscal Year: 2004
    ..The result of this work should be the creation of new, more rapid tools for determining free drug or hormone levels, providing a better means for studying how such compounds behave and interact within our bodies. ..
  19. POLYMERASE INTERACTIONS WITH CARCINOGEN MODIFIED DNA
    F Guengerich; Fiscal Year: 2004
    ..The overall goal is understanding molecular mechanisms of mutagenesis as a part of chemical carcinogenesis. ..
  20. CHROMATOGRAPHIC STUDIES OF FUNCTIONAL PROTEOMICS
    DAVID HAGE; Fiscal Year: 2007
    ..This, in turn, should allow an improved description of how the transport, metabolism, and effective dose of a drug will differ between a diabetic patient and an individual without diabetes. ..
  21. Design and Characterization of DNA Interactive Agents
    Jennifer Brodbelt; Fiscal Year: 2005
    ..The anticancer and antibacterial effects of UK-1 and A-62176 analogs will be examined in a range of human cancer cell lines and Gram negative and Gram positive bacteria. ..
  22. Hyopthyroidism Treatment in Aging and Thyroid Cancer
    Offie P Soldin; Fiscal Year: 2010
    ..This will help in setting therapeutic goals and help millions in diagnosis, treatment and management of thyroid disease in aging. ..
  23. Analysis of Phenolic Phytochemical by ESI-MS
    Jennifer Brodbelt; Fiscal Year: 2003
    ....
  24. MECHANISMS OF TOXICITY GORDON CONFERENCE
    RONALD HINES; Fiscal Year: 2002
    ..There also is substantial involvement of new personnel as Chairs and co-Chairs. Thus, the Mechanism of Toxicity GRC is poised to continue its growth as the single leading small conference on Molecular Toxicology. ..
  25. Super-persistent cells and the paradox of untreatable infections
    Kim Lewis; Fiscal Year: 2009
    ..Our findings are likely to change the way we view infectious diseases and will provide rational approaches for discovering drugs that completely eradicate the infection. ..
  26. Physiological functions of G-alpha-i/o and control by regulators of G protein sig
    Richard R Neubig; Fiscal Year: 2010
    ..By improving those therapeutically useful signals at the expense of signals leading to side effects, we can produce better medicines or can make existing medicines better tolerated. ..
  27. Design of Small Molecules Acting at Regulators of G Protein Signaling
    Richard R Neubig; Fiscal Year: 2010
    ..This project will provide the initial steps and proof of principle for medications development targeting RGS proteins - a key modulator of signaling related to drug abuse. ..
  28. Design of Small Molecules Acting at Regulators of G Protein Signaling
    Richard Neubig; Fiscal Year: 2007
    ..This project will provide the initial steps and proof of principle for medications development targeting RGS proteins - a key modulator of signaling related to drug abuse. ..
  29. PEPTIDE MODULATORS OF G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 1993
    ....
  30. PEPTIDE MODULATORS OF G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 2000
    ..The specificity of these "drugs" will be tested in cell culture with the aim of future use in gene therapy approaches to cardiovascular disease. ..
  31. Biophysical Studies of G Protein Activation/Deactivation
    Richard Neubig; Fiscal Year: 2003
    ..The studies in this proposal should permit a better understanding of rapid G protein activation and deactivation mechanisms and will explore the potential of RGS proteins as a novel target of drug action. ..